Additionally, LCN2 plasma levels were increased in preclinical AD, classified accordingly to the CSF Aβ42, total tau and phosphorylated tau levels, compared to controls (Eruysal et al., 2019). This evidence concerns the gene MAPT and Alzheimer disease.